A urine dipstick reading of glucose is usually mundane, but a few presentations behind it are emergencies. The classic trap is the lean young person with osmotic symptoms and weight loss: that is new type 1 diabetes and may already be ketoacidotic, so it needs a same-day capillary glucose and ketone check rather than a routine fasting test. The examiner-critical NG12 link is pancreatic cancer — new diabetes after 60 with weight loss is a recognised prompt for urgent pancreatic imaging. And in patients on SGLT2 inhibitors, ketoacidosis can occur with near-normal glucose, so unwellness, not the glucose number, triggers the ketone check.

Everything in glycosuria flows from one idea: the kidney spills glucose either because the blood level is too high or because the threshold for reabsorption is too low. That single split — hyperglycaemic versus normoglycaemic glycosuria — decides whether the patient has diabetes or simply a benign low renal threshold. Because the dipstick cannot tell these apart, the indispensable next step is always a paired blood glucose, and the commonest error is to reassure (or alarm) a patient on the strength of the urine result alone.

The history quickly biases you towards one side of the split. Osmotic symptoms — thirst, polyuria, recurrent genital thrush — argue for genuine hyperglycaemia and prompt confirmatory bloods without delay, while the same picture with weight loss in a lean patient escalates to a same-day pathway. The single most important question in modern practice is the drug history: a patient on an SGLT2 inhibitor is expected to have glucose in the urine, and missing that leads to needless diabetes work-ups. Pregnancy and family history fill in the benign low-threshold causes.

The differential keeps the benign and the serious causes side by side. Most glycosuria with hyperglycaemia is type 2 diabetes, but the list must stay open to type 1 in the young or lean, to the secondary causes — with pancreatic cancer flagged under NG12 — and to the entirely benign normoglycaemic causes (familial renal glycosuria, SGLT2 inhibitors, pregnancy). Fanconi syndrome is the clue to look beyond glucose: if the urine is also losing amino acids and phosphate, the problem is the proximal tubule, not glycaemia.

Investigation is built around the paired blood glucose. A fasting glucose and HbA1c confirm or exclude diabetes and, when raised, stage it; if the patient is unwell, the work-up shifts immediately to ketones and a gas to catch acidosis. Where blood glucose is normal but glycosuria persists, the tests have effectively made the diagnosis — renal glycosuria — and the discipline is to stop, reassure, and not subject the patient to a diabetes pathway. The secondary screens, including NG12 pancreatic imaging, are deployed only when the history points to them.

Referral is dominated by two urgent routes and one cancer pathway. Suspected type 1, DKA or HHS go to hospital the same day — and any child with new diabetes is a same-day specialist referral, never an oral-agent start in primary care. New diabetes after 60 with weight loss triggers the NG12 pancreatic-imaging route. Around these, routine endocrinology handles diagnostic uncertainty and secondary causes, nephrology handles tubular disorders, and confirmed gestational diabetes goes to the joint antenatal clinic.

The therapeutic principle is to treat the underlying state, never the dipstick. Renal glycosuria and the glycosuria of SGLT2 inhibitors need nothing more than explanation. Confirmed type 2 diabetes enters the usual lifestyle-plus-metformin pathway with cardio-renal-driven add-ons, whereas suspected type 1 must go to specialist care for insulin — trialling oral agents here is dangerous. Urine glucose has no role in monitoring modern diabetes, so the old habit of titrating to the dipstick is abandoned in favour of HbA1c and capillary or continuous glucose.

Lifestyle advice is tailored to which side of the split the patient sits on. For benign renal glycosuria the highest-value intervention is reassurance, sparing the patient unnecessary diets and repeat tests. For confirmed or at-risk type 2 diabetes the familiar package — weight loss, reduced refined carbohydrate, activity and smoking cessation — modifies the disease and can achieve remission. Patients on SGLT2 inhibitors need specific counselling on genital hygiene, sick-day rules and ketone awareness, because their glycosuria is intentional but carries its own small risks.

Safety-netting closes the two ways glycosuria goes wrong. The first is under-calling an emergency: osmotic symptoms with weight loss, vomiting or drowsiness — or any unwell patient on an SGLT2 inhibitor — needs a same-day ketone and glucose assessment for DKA. The second is the missed cancer: new diabetes in an older adult with weight loss should never be filed as benign without considering NG12 pancreatic imaging. For the genuinely normoglycaemic patient, the safety-net is the opposite — firm reassurance and discharge, so a benign dipstick does not become a lifetime of anxious re-testing.